Reva raises $42M in financing for bioresorbable stent development

TriMed Staff | | Health Imaging | Diagnostic Imaging
Reva Medical, a company developing bioresorbable stents, has raised $42 million in a private financing led by Cerberus Capital Management and Brookside Capital, an affiliate of Bain Capital.

Pequot Capital Management and Medtronic, as well as previous investors, Domain Partners and Group Outcome, also participated in the round of financing.

The San Diego-based Reva said the proceeds will be used to continue the development and clinical testing of its bioresorbable stent products.

Boston Scientific maintains its equity position in Reva and will hold an exclusive option for global distribution for its resorbable coronary and peripheral stent products, according to Reva.

TriMed Staff

Related Content

First human X-rays in space to take place during upcoming SpaceX mission
Mycoplasma pneumonia: Experts highlight imaging findings linked to the pediatric diagnosis
AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.